Several studies have utilised the PARP inhibitor olaparib as a radiosensitizer, although these have shown mixed results particularly regarding degree of radiosensitisation of HPV-negative HNSCC cell lines, which are deemed DSB repair proficient. The gene discussed is PARP1; the disease is head and neck squamous cell carcinoma.